🚀 VC round data is live in beta, check it out!
Pharmaron Beijing Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pharmaron Beijing and similar public comparables like Dixon Technologies, Repligen, Sonic Healthcare, Fortis Healthcare and more.
Pharmaron Beijing Overview
About Pharmaron Beijing
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
Founded
2004
HQ
Employees
21.4K
Website
Financials (LTM)
EV
$8B
Pharmaron Beijing Financials
Pharmaron Beijing reported last 12-month revenue of $2B and EBITDA of $514M.
In the same LTM period, Pharmaron Beijing generated $770M in gross profit, $514M in EBITDA, and $259M in net income.
Revenue (LTM)
Pharmaron Beijing P&L
In the most recent fiscal year, Pharmaron Beijing reported revenue of $2B and EBITDA of $486M.
Pharmaron Beijing expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $770M | XXX | $720M | XXX | XXX | XXX |
| Gross Margin | 36% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | $514M | XXX | $486M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $259M | XXX | $244M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $296M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pharmaron Beijing Stock Performance
Pharmaron Beijing has current market cap of $8B, and enterprise value of $8B.
Market Cap Evolution
Pharmaron Beijing's stock price is $4.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $8B | -3.0% | XXX | XXX | XXX | $0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPharmaron Beijing Valuation Multiples
Pharmaron Beijing trades at 3.9x EV/Revenue multiple, and 16.2x EV/EBITDA.
EV / Revenue (LTM)
Pharmaron Beijing Financial Valuation Multiples
As of April 18, 2026, Pharmaron Beijing has market cap of $8B and EV of $8B.
Equity research analysts estimate Pharmaron Beijing's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pharmaron Beijing has a P/E ratio of 29.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 16.2x | XXX | 17.2x | XXX | XXX | XXX |
| EV/EBIT | 25.7x | XXX | 25.6x | XXX | XXX | XXX |
| EV/Gross Profit | 10.8x | XXX | 11.6x | XXX | XXX | XXX |
| P/E | 29.2x | XXX | 31.0x | XXX | XXX | XXX |
| EV/FCF | 72.7x | XXX | 103.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pharmaron Beijing Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pharmaron Beijing Margins & Growth Rates
Pharmaron Beijing's revenue in the last 12 month grew by 16%.
Pharmaron Beijing's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Pharmaron Beijing's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pharmaron Beijing's rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Pharmaron Beijing Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 19% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 12% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pharmaron Beijing Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing and Laboratory Services comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pharmaron Beijing | XXX | XXX | XXX | XXX | XXX | XXX |
| Dixon Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Repligen | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Fortis Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| ALS | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharmaron Beijing M&A Activity
Pharmaron Beijing acquired XXX companies to date.
Last acquisition by Pharmaron Beijing was on XXXXXXXX, XXXXX. Pharmaron Beijing acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pharmaron Beijing
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPharmaron Beijing Investment Activity
Pharmaron Beijing invested in XXX companies to date.
Pharmaron Beijing made its latest investment on XXXXXXXX, XXXXX. Pharmaron Beijing invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pharmaron Beijing
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pharmaron Beijing
| When was Pharmaron Beijing founded? | Pharmaron Beijing was founded in 2004. |
| Where is Pharmaron Beijing headquartered? | Pharmaron Beijing is headquartered in China. |
| How many employees does Pharmaron Beijing have? | As of today, Pharmaron Beijing has over 21K employees. |
| Who is the CEO of Pharmaron Beijing? | Pharmaron Beijing's CEO is Boliang Lou. |
| Is Pharmaron Beijing publicly listed? | Yes, Pharmaron Beijing is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Pharmaron Beijing? | Pharmaron Beijing trades under 300759 ticker. |
| When did Pharmaron Beijing go public? | Pharmaron Beijing went public in 2019. |
| Who are competitors of Pharmaron Beijing? | Pharmaron Beijing main competitors are Dixon Technologies, Repligen, Sonic Healthcare, Fortis Healthcare. |
| What is the current market cap of Pharmaron Beijing? | Pharmaron Beijing's current market cap is $8B. |
| What is the current revenue of Pharmaron Beijing? | Pharmaron Beijing's last 12 months revenue is $2B. |
| What is the current revenue growth of Pharmaron Beijing? | Pharmaron Beijing revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Pharmaron Beijing? | Current revenue multiple of Pharmaron Beijing is 3.9x. |
| Is Pharmaron Beijing profitable? | Yes, Pharmaron Beijing is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pharmaron Beijing? | Pharmaron Beijing's last 12 months EBITDA is $514M. |
| What is Pharmaron Beijing's EBITDA margin? | Pharmaron Beijing's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Pharmaron Beijing? | Current EBITDA multiple of Pharmaron Beijing is 16.2x. |
| What is the current FCF of Pharmaron Beijing? | Pharmaron Beijing's last 12 months FCF is $115M. |
| What is Pharmaron Beijing's FCF margin? | Pharmaron Beijing's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Pharmaron Beijing? | Current FCF multiple of Pharmaron Beijing is 72.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.